Article

Blue-blocking IOL can hinder scotopic vision, expert says

IOLs that block blue light, such as the AcrySof Natural IOL (Alcon Laboratories), trade scotopic visual performance for limited protection against acute UV-blue retinal phototoxicity, and they are a particularly poor choice for individuals whose scotopic vision is impaired because of conditions such as age-related macular degeneration (AMD) and diabetic retinopathy, according to Martin A. Mainster, PhD, MD, FRCOphth.

Editor's Note: In the following report, Martin A. Mainster, PhD, MD, FRCOphth, contends that IOLs that filter blue light provide minimal protection against acute UV-blue retinal toxicity and limit scotopic vision. In another article, Janet R. Sparrow, PhD, presents the results of a tissue culture study in which the blue light-absorbing design of one IOL was shown to protect retinal pigment epithelial cells from the damaging effects of light.

Dr. Mainster has been studying phototoxicity for several decades. During the second year of his ophthalmology residency in 1978, he published two papers warning that clear IOLs transmitted potentially harmful UV radiation between 330 and 400 nm to the retina.1,2 Within a decade, most IOLs were manufactured with UV-blocking chromophores. Dr. Mainster suggested in 1986 that it might be useful to block violet light in addition to UV radiation to reduce the risk of acute UV-blue phototoxicity.

"Ultraviolet accounts for 67% of acute UV-blue phototoxicity between 350 and 700 nm. Violet light is responsible for 18% of acute UV-blue phototoxicity, but it contributes only 5% of scotopic vision. That's why I suggested blocking violet light with IOL chromophores in 1986," Dr. Mainster said.3

"Conversely, blue light is responsible for 14% of UV-blue phototoxicity, but it provides more than 40% of scotopic vision. That's why I did not recommend blocking blue light. In addition to restricting UV radiation and violet light, the AcrySof Natural IOL limits blue and even some green light."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.